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Functional interaction between the cytoplasmic leucine-zipper
domain of HIV-1 gp41 and p115-RhoGEF
H. Zhang*, L. Wang*, S. Kao†, I.P. Whitehead*, M.J. Hart‡, B. Liu§, K. Duus*,
K. Burridge*§, C.J. Der*¶ and L. Su*†
The long cytoplasmic tail of the human
immunodeficiency virus (HIV)-1 transmembrane protein
gp41 (gp41C) is implicated in the replication and
cytopathicity of HIV-1 [1]. Little is known about the
specific functions of gp41C, however. HIV-1 or simian
immunodeficiency virus (SIV) mutants with defective
gp41C have cell-type- or species-dependent phenotypes
[2–6]. Thus, host factors are implicated in mediating the
functions of gp41C. We report here that gp41C
interacted with the carboxy-terminal regulatory domain
of p115-RhoGEF [7], a specific guanine nucleotide
exchange factor (GEF) and activator of the RhoA
GTPase, which regulates actin stress fiber formation,
activation of serum response factor (SRF) and cell
proliferation [8,9]. We demonstrate that gp41C inhibited
p115-mediated actin stress fiber formation and
activation of SRF. An amphipathic helix region with a
leucine-zipper motif in gp41C is involved in its
interaction with p115. Mutations in gp41C leading to
loss of interaction with p115 impaired HIV-1 replication
in human T cells. These findings suggest that an
important function of gp41C is to modulate the activity
of p115-RhoGEF and they thus reveal a new potential
anti-HIV-1 target. 
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Results and discussion
The gp41C domain interacts with the carboxy-terminal
regulatory domain of p115-RhoGEF
To elucidate the function of gp41C, we performed a yeast
two-hybrid screen to identify proteins that interact with it
(see Supplementary material). From 5 × 106 cDNA clones,
four clones were identified. One encodes the carboxy-ter-
minal 60 residues (gh60) of p115-RhoGEF and the other
three all encode its carboxy-terminal 53 residues (g117;
Figure 1). To confirm the interaction of p115-RhoGEF
with gp41C in mammalian cells, we co-expressed p115 pro-
teins with a gp41C protein fused to six histidine residues at
the amino terminus (His6–gp41C) and labeled the cells
with [35S]methionine and [35S]cysteine. His6–gp41C was
precipitated with Ni–NTA beads and gp41C-associated
proteins were visualized by autoradiography (Figure 1b).
The full-length p115 (p115FL) was coprecipitated with
gp41C (lane 4), and p115FL alone was not precipitated by
the Ni–NTA beads (lane 3). The p115dC protein, which
lacks the carboxy-terminal 100 residues [7], was not copre-
cipitated with His6–gp41C (lane 5). These results were
consistent with our findings from yeast cells, in which
gp41C interacted with the carboxy-terminal 53 residues of
p115 (g117, Figure 1c). Like other Dbl-family Rho GEFs,
p115-RhoGEF is associated with the plasma membrane
through its pleckstrin homology (PH) domain [9,10]. To
show colocalization of p115-RhoGEF with HIV-1 gp41,
p115FL was cotransfected with the HIV-1 provirus pNL4-
3 in HeLa cells. Double staining with a rhodamine-labeled
anti-p115 antiserum and a fluorescein isothiocyanate
(FITC)-labeled anti-gp41C monoclonal antibody showed
that gp41 and p115 were both localized in the cytoplasmic
membrane region (Figure 1d). Thus, gp41 may be associ-
ated with p115 at the plasma membrane.
Expression of gp41C disrupts actin stress fiber organization
To test whether gp41C affected p115 activity, we studied
the effect of gp41C on actin stress fiber formation in Swiss
3T3 cells [11]. Cells overexpressing p115FL or p115dC
showed enhanced actin stress fiber formation and increased
phalloidin staining (Figure 2a,g). Non-injected cells had
low levels of actin stress fibers. Expression of gp41C led to
a disruption of the actin stress fibers (Figure 2c). Co-expres-
sion of p115FL or p115dC with gp41C led to reorganized
actin stress fibers (Figure 2e,g). Therefore, gp41C inhibited
actin stress fiber formation. Co-expression of active p115-
RhoGEF counteracted the inhibitory activity of gp41C.
Ectopic expression of gp41C inhibits p115-mediated SRF
activation
We further showed that gp41C inhibited p115-mediated
activation of SRF, which is activated by Rho GTPases [12].
An SRF-responsive reporter gene was activated by p115 in
serum-starved NIH 3T3 cells (Figure 2i). Co-expression
of gp41C inhibited this p115-mediated activation. This
inhibition depended on the interaction between gp41C
and p115 because p115dC, which did not interact with
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Figure 2
Inhibition of p115-RhoGEF-mediated RhoA activation by gp41C.
(a–h) Disruption of actin stress fiber organization by gp41C. Swiss
3T3 cells were micro-injected with plasmid DNA and serum-starved
for 12–16 h before fixation and staining of actin stress fibers.
(a,b) Cells injected with Myc-tagged p115FL alone; (c,d) cells
injected with a plasmid encoding enhanced green fluorescent protein
under the control of the CMV promoter (pCMV–eGFP) and
pcHgp41C; (e,f) cells injected with p115FL and pcHgp41C;
(g,h) cells injected with Myc-tagged p115dC and pcHgp41C. The
injected cells (arrows) were identified either (d) by GFP signals or
(b,f,h) by immunostaining of the Myc epitope-tagged p115 proteins.
The rhodamine–phalloidin-stained stress fibers were visualized in
(a,c,e,g). Representatives of about 20 microinjected cells for each
sample are shown. Two independent experiments were performed.
(i) Inhibition of p115-RhoGEF-mediated activation of SRF by gp41C.
A plasmid with a luciferase gene controlled by a mutant c-Fos serum
response element (SREm2-Luc) that no longer responds to ternary
complex factor (TCF) and measures only SRF activity (see
Supplementary material) was co-expressed with plasmids encoding
fragments of gp41 and/or p115, and luciferase activity was
measured. Co-expression of gp41C inhibited p115FL-mediated
activation by 70% (p115+gp41C), but did not inhibit p115dC-
mediated activation (p115dC+gp41C) or FGD1-activated SRF
(FGD1+gp41C). The experiments were performed in triplicate and
repeated three times. Error bars indicate standard deviations.
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Figure 1
Interaction of gp41C with the carboxyl terminus of p115-RhoGEF.
(a) Two-hybrid assay. The g117 fragment (the carboxy-terminal 53
residues of p115-RhoGEF) interacts with gp41C to activate the his3
gene and the lacZ gene. CDK6 and p18-INK4c were used as positive
controls. Yeast colonies that grew on plates lacking leucine and
tryptophan (–LW) were tested for the expression of lacZ (–LW/X-gal)
or on histidine-deficient plates (–LWH). (b) Coprecipitation of p115
with His6–gp41C in transfected 293T cells. The His6–gp41C
(encoded by plasmid pcHgp41C) was pelleted with Ni–NTA beads
and pelleted proteins were visualized after autoradiography. Lanes 1–5
show samples from cells transfected with pcDNA3 vector alone
(lane 1), pcHgp41C and pcDNA3 (lane 2), p115FL and pcDNA3
(lane 3), pcHgp41C and p115FL (lane 4), or pcHgp41C and p115dC
(lane 5). Both p115FL and p115dC were efficiently expressed (data
not shown). (c) Schematic representation of the structure and function
of the p115 derivatives. Protein p115FL, full-length p115; p115dC, a
truncated p115 fragment (residues 249–802); gh60 and g117, the
gp41C-interacting fragments isolated from the two-hybrid assays
(residues 853 (gh60) or 860 (g117) to 913 of p115-RhoGEF). GEF,
guanine nucleotide exchanging activity on RhoA [7]; gp41C, interaction
with the gp41C protein (in yeast and 293T cells); DH, Dbl homology
region; PH, pleckstrin homology region. (d) Colocalization of gp41 and
p115-RhoGEF. HeLa cells were cotransfected with DNAs encoding
p115 and HIV-1 provirus NL4-3. Cells were stained with an anti-p115
antiserum [7] and an anti-gp41 monoclonal antibody. Secondary
antibodies (rhodamine-labeled goat anti-rabbit and FITC-labeled anti-
mouse) were used to detect p115 and gp41, respectively. Pre-immune
or isotype controls showed no significant staining (data not shown).
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gp41C, also activated the SRF reporter but gp41C co-
expression failed to inhibit its activity (Figure 2i). Further-
more, gp41C showed no inhibition of SRF activation
mediated by other Rho GEFs such as FGD1 [13]
(Figure 2i) and Dbl (data not shown). Therefore, gp41C
interacted with p115-RhoGEF to inhibit its activity.
Further investigation of the interaction between gp41C
and p115 should help to elucidate the mechanism of GEF-
mediated Rho activation.
Inhibition of p115-mediated activation of RhoA by gp41C
has significant implications for HIV-1 pathogenesis. First,
inhibition of RhoA activity has been reported to enhance
the spreading and migration of monocytes and macrophages
[14]. Thus, gp41C may interact with p115-RhoGEF to
modulate target-cell migration from the initial site of infec-
tion. Second, RhoA is also involved in regulating cell sur-
vival and cell-cycle progression [15,16]. Inhibition of
p115-RhoGEF (or RhoA) activity by gp41C may lead to
depletion of human T cells and progenitor cells [17,18]. 
A putative leucine-zipper motif in gp41C is involved in the
interaction with p115-GEF
Several structural motifs implicated in protein–protein inter-
action and signal transduction are present in gp41C
(Figure 3a). Two lentivirus lytic peptides (LLP1 and LLP2)
interact with calmodulin [19] and inhibit Ca2+-dependent
T-cell activation [20]. A leucine-zipper motif (790–811) has
recently been shown to bind lipid membranes [21]. To map
the region of gp41C required for the interaction with p115,
gp41C was dissected by deletion analysis (Figure 3a). Dele-
tion of 12 or more residues at the carboxyl terminus
(dC1–dC6) abolished interaction with p115 (g117). Deletion
of the amino-terminal 52 residues of gp41C (dN1), however,
had no effect on the interaction. When the LLP2 sequences
were deleted (dN2), interaction with p115 was lost. Thus,
the carboxy-terminal 98 residues of gp41C, containing the
two LLPs and the leucine-zipper motif, are necessary and
sufficient to mediate interaction of gp41C with p115. 
To define specific residues in gp41C involved in direct
interaction with p115, a modified ‘reverse’ two-hybrid
assay (see Supplementary material) was performed. Four
out of five mutants identified carried mutations in the
amphipathic helix region of gp41C that encodes the puta-
tive leucine-zipper motif (Figure 3b). The fifth mutation
was in the LLP1 region (data not shown). The four
leucine-zipper mutations (tryptophan to serine or arginine
and serine to arginine) resulted in an increase in charge on
the hydrophobic side of the amphipathic helix. To further
confirm that the leucine-zipper motif is involved, we
introduced an arginine replacing the second leucine in the
leucine-zipper motif (L95R), which also led to loss of
interaction with p115. 
Loss of interaction between gp41C and p115-RhoGEF
impaired HIV-1 replication
To prove genetically the importance of the interaction
between gp41C and p115, the L95R mutation was intro-
duced into the HIVNL4–3 genome. The HIV-1 NL4(L95R)
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Figure 3
A putative leucine-zipper (LZ) motif of gp41C is
involved in the interaction with p115.
(a) Mapping of the gp41C domains involved in
interaction with the carboxyl terminus of p115-
RhoGEF. TM, transmembrane domain; LLP1
and LLP2, lentivirus lytic peptides. The
numbers 1–854 indicate residue positions in
the HIV-1 gp160 env polypeptide. The residues
after the TM domain (704–854) are referred to
as gp41C and numbered 1–151. The
fragments gp41C (1–151), dC1 (1–47), dC2
(1–70), dC3 (1–90), dC4 (1–97), dC5
(1–108), dC6 (1–139), dN1 (53–151), and
dN2 (83–151) were fused to the Gal4 DNA-
binding domain. Binding to g117 (+ or –) was
determined by growth on His– plates and
expression of lacZ, as in Figure 1. (b) Mutations
defined by the reverse yeast-two-hybrid screen
are localized around the LZ region. The
amphipathic α-helix region containing the LZ
motif is shown in the single-letter amino acid
code and the leucines comprising the LZ motif
(LX6LX6LX6L, where X is any amino acid) are in
bold. The mutations defined by the reverse two-
hybrid screen leading to loss of interaction with
g117 are marked.
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mutant produced wild-type levels of infectious virions
when transfected into 293T cells (data not shown). When
human leukemia T cells (SupT1, H9, and Jurkat cells)
were infected, the L95R mutant had impaired replication
(Figure 4). Therefore, the interaction of gp41C with p115
correlated with enhanced HIV-1 replication in human T-
cell lines. This interaction provides a new host target
(p115-RhoGEF) and a new viral target (gp41C) for the
development of anti-HIV therapies.
Supplementary material
Supplementary material including additional experimental details is
available at http://current-biology.com/supmat/supmatin.htm.
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The interaction between gp41C and p115-RhoGEF correlates with
HIV-1 replication in human T-cell lines. SupT1, H9 or Jurkat cells were
infected with an equal number of infectious units of NL4-3 or
NL4(L95R) mutant viruses. Viral replication (as measured by reverse
transcriptase activity) was monitored every 3 days for 18 days after
infection. The experiments were repeated three times with similar results.
Functional interaction between the cytoplasmic leucine-zipper
domain of HIV-1 gp41 and p115-RhoGEF
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Supplementary materials and methods
Reagents, plasmids and cell lines
The cDNA encoding the cytoplasmic domain of gp41 (the carboxy-ter-
minal 150 residues) was cloned into the yeast two-hybrid ‘bait’ vector
(pGBT8, ClonTech) such that it was fused in frame with the DNA
binding domain of Gal4, to generate pGBT8-gp41C [S1]. Sequences
encoding His–gp41C, p115FL, and p115dC were all cloned into the
pcDNA3 mammalian expression vector (InVitrogen). The lacZ, FGD-1,
and Dbl cDNAs were cloned in the pAX142 mammalian expression
vector [S2]. The luciferase gene controlled by a mutant c-Fos serum
response element (SREm2-Luc) that no longer responds to TCF and
measures only SRF activity was described previously [S3]. 
The 293T and HeLa cell lines (American Type Culture Collection,
ATCC) were maintained in DMEM supplemented with 10% FBS and
NIH 3T3 and Swiss 3T3 cells were cultured in DMEM supplemented
with 10% newborn calf serum. Cells were seeded on six-well plates
(2 × 105 cells per well) the day before transfection or microinjection.
Jurkat, SupT1 (ATCC), and H9 cells were maintained in RPMI-1640
supplemented with 10% FBS.
Yeast two-hybrid screening
Plasmid pGBT8-gp41C was used as a bait to screen a human thymus-
derived and HeLa-derived yeast two-hybrid library (ClonTech). About
5 × 106 independent colonies were screened, and 187 colonies that
grew on His-deficient plates were further screened for their β-galactosi-
dase production. Four clones were chosen for further analysis because
they encoded peptides that interacted strongly with gp41C to activate
both the His and lacZ reporter genes. Positive clones were first ana-
lyzed by PCR to determine the size of the insert. The expected clones
were then recovered from yeast cells by DNA extraction and transfor-
mation into E. coli (Matchmaker, ClonTech). The putative clones were
further confirmed by cotransfecting with the pGBT8-gp41C bait
plasmid in yeast cells. PCR products from the recovered plasmids
were sequenced by the dideoxynucleotide termination method
(Lineberger Comprehensive Cancer Center sequencing facility, Univer-
sity of North Carolina at Chapel Hill). The BLAST program was used to
search the DNA databases.
Reverse yeast-two-hybrid screening
The gp41C region was mutagenized by PCR as described [S4].
Briefly, the dTTP concentration was limited so that about one misincor-
poration of nucleotides (dGTP, dATP or dCTP) was introduced for
each gp41C PCR product. The PCR products were cotransformed
with the pGBT8 vector, cut in the cloning region, into the yeast Y7
strain stably expressing the g117 (p115) prey. Gap repair activity in
yeast ligated the mutagenized gp41C fragments into the pGBT8 vector
[S4]. The yeast colonies were screened for their growth on
Leu–Trp–His– plates and their expression of lacZ was analyzed using a
β-galactosidase assay. The His–/lacZ– mutants were confirmed and
sequenced to identify the mutations that led to the loss of interaction.
Coprecipitation assays
A plasmid encoding His–gp41C (pcHgp41C) was cotransfected with
vector DNA or plasmid DNA encoding p115-RhoGEF (p115FL or
p115dC) into 293T cells with Lipofectamine (Gibco BRL). In each
transfection with 4 µl of the Lipofectamine reagent, 2 µg of total
plasmid DNA (1 µg for each plasmid) was used. The pcDNA3 vector
was used in transfections where only one effector plasmid was
included. Cells were radiolabeled with [35S]methionine and [35S]cys-
teine (80 µCi per well, Dupont NEN) for 16 h (from 32 h to 48 h after
transfection). Cell extracts were prepared by lysis of cells (5 × 106 per
well) in 0.5 ml of lysis buffer (0.1% Triton X-100, 50 mM Tris–HCl
pH 7.5, 150 mM NaCl, 50 mM NaF, 1 mM NaVO3) with protease
inhibitors (0.1 mM each PMSF, aprotinin, leupeptin, and pepstatin) on
ice for 30 min, followed by 10 min centrifugation in a microcentrifuge
(12,000 × g) at 4°C. His–gp41C protein was directly pelleted with
Ni–NTA-beads (KIAGEN). Precipitated proteins were analyzed by
SDS–PAGE followed by direct autoradiography.
Immunostaining of p115-RhoGEF and HIV-1 gp41
HeLa cells were cotransfected with DNAs encoding p115 and HIV-1
provirus NL4-3 [S5]. Cells were processed at 40 h after transfection with
an anti-p115 antiserum [S6] and an anti-gp41 monoclonal antibody
(kindly provided by the NIH AIDS Research and Reagent Program). Sec-
ondary antibodies (rhodamine-labeled goat anti-rabbit and FITC-labeled
anti-mouse) were used to detect p115 and gp41, respectively. Immunoflu-
orescence staining and photography were performed as described [S7].
Actin stress fiber staining
Swiss 3T3 cells were micro-injected with pcHgp41C (and/or a plasmid
encoding Myc-tagged p115) and pCMV–GFP. After incubation for
18 h in serum-free DMEM, the injected cells were analyzed by
immunostaining for actin stress fibers and Myc–p115 essentially as
described [S8]. Briefly, cells were fixed in formaldehyde (3.7% in PBS)
for 10 min and permeabilized in Triton X-100 (0.5%) for 6 min. They
were then incubated with anti-Myc antibody, followed by FITC-conju-
gated goat anti-mouse immunoglobulin G and rhodamine-conjugated
phalloidin (Molecular Probes). Injected cells were visualized by stan-
dard fluorescence microscopy for GFP, rhodamine (for actin stress
fibers) or FITC (for Myc).
Rho-dependent SRF reporter assays
Briefly, plasmids encoding p115 (or p115dC, FGD-1 or Dbl), gp41C,
and SREm2-Luc were transfected into NIH 3T3 cells. The cells were
serum-starved from 24 h to 36 h after transfection and a luciferase
assay was performed using enhanced chemiluminescent reagents and
a Monolight 2010 Luminometer (Analytical Luminescence). All assays
were performed in triplicate and repeated at least three times. The
internal control reporter plasmid pAX142-lacZ was included in the
transfection mix and all values were normalized relative to β-galactosi-
dase activity. No significant difference in β-galactosidase activity was
observed between different samples.
Construction of NL4(L95R) gp41 mutant
To construct an infectious NL4-3 proviral clone containing the L95R
mutation in gp41, primer L95RF (5′-TGGGAAGCCCTCAA
ATATTGGTGGAATCTCCGACAGTATTGGAGTCAG-3′, nucleotides
8590–8637; the mutated nucleotide is in bold) and L95RR
(5′-CTGACTCCAATACTGTCGGAGATTCCACCAATATTTGAGGGC
TTCCCA-3′, nucleotides 8367–8590) were used to perform site-
directed mutagenesis in the plasmid pBS.HIV/NL4-3.SalI/XbaI using
the QuikChange site-directed mutagenesis kit (Stratagene). Plasmid
pBS-NL4-SalI/XbaI is a pBS (Stratagene)-based vector containing the
SalI-XhoI fragment of NL4-3 [S5]. The mutated BamHI–XhoI fragment
was sequenced and cloned into the NL4-3 proviral DNA clone. The
Supplementary material
resulting proviral clone (pNL/L95R) was sequenced to confirm the
mutation. The Rev protein encoded by the other reading frame was
not altered.
HIV-1 viral stock production and virus-replication assays
The pNL/L95R mutant or pNL4-3 plasmid was transfected into 293T
cells. Virus production was measured with a reverse transcriptase
assay and an infectious-units assay on MAGI cells [S9]. HIV-1 replica-
tion was performed as described [S10]. Briefly, about 3,000 infectious
units of NL4-3 or L95R mutant were used to infect 0.5 × 106 T cells
(SupT1, Jurkat or H9). HIV-1 replication was monitored every three
days by reverse transcriptase assay in culture medium.
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